In patients with localized triple-negative breast cancer and residual disease at time of surgery following neoadjuvant KEYNOTE-522 regimen, when would you recommend adding adjuvant capecitabine or another agent to pembrolizumab?  

Patient is BRCA 1/2 wild type; completed four cycles of carboplatin/paclitaxel and two cycles of AC with pembrolizumab in the neoadjuvant setting.

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution